See some signs of hope in dark economic times as panelists explore some of the mind-boggling innovations that are changing our lives and can shape the future of the country. Even in the midst of economic free fall, there are signs of hope.
As of January 2009, the United States has built a flying car, found ways to turn algae into fuel, synthetically reproduced organs, had face-to-face conversations with people on the other side of the planet, and built robots to do our house cleaning for us.
Tune in to find out how some of the smartest people in California are trying to innovate us out of disaster.
Managing Partner of Pacific Rim Partners, Richard Dare is responsible for identifying cross-border opportunities. Dare has consummated significant international deals with Mitsubishi, NTT Communications and Pioneer Corporation.
Dare began his career as an adjunct Professor of Cognitive Field Theories, lecturing widely in the U.S., England and Japan.
David Ewing Duncan
David Ewing Duncan is an award-winning, best-selling author of eight books published in 21 languages. He is a founder and co-curator of Arc Programs. David is a columnist for Newsweek, a correspondent for The Atlantic and the chief correspondent for NPR Talk’s Biotech Nation. David writes for The New York Times, Fortune, Wired, National Geographic, Discover and many other publications. He is a former commentator for NPR’s Morning Edition and a special correspondent and producer for ABC’s Nightline and 20/20, and correspondent for NOVA’s ScienceNow!. His latest book is When I’m 164: The new science of radical life extension, and what happens if it succeeds. He also wrote Experimental Man: What One Man’s Body Reveals about His Future, Your Health, and Our Toxic World (Wiley). He was the founder and director of the BioAgenda Institute, and the founding director of the Center of Life Science Policy at UC Berkeley. David is finishing his first novel, a biomedical thriller. David’s work has won numerous awards, including Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. David lives in San Francisco and is a member of the SF Writer’s Grotto. His website is www.davidewingduncan.com.
Drew Endy helped start the newest engineering major, Bioengineering, at both MIT and Stanford. His research teams pioneered the redesign of genomes and invented the transcriptor, a simple DNA element that allows living cells to implement Boolean logic. He is also a co-founder of Gen9, Inc., a DNA construction company, and the iGEM competition.
Paul Saffo is a forecaster with over two decades experience exploring the dynamics of large-scale, long-term change. He is Managing Director of Foresight at Discern Analytics, teaches at Stanford University and is a researcher through mediaX at Stanford University. Saffo serves on a variety of not-for-profit boards including the Long Now Foundation, and the Bay Area Council Economic Institute. Saffo’s essays have appeared in a wide range of publications including The Harvard Business Review, Fortune, Wired, The Los Angeles Times, Newsweek, The New York Times, and the Washington Post. Saffo holds degrees from Harvard College, Cambridge University and Stanford University.
Jonathan Wolfson is CEO of Solazyme. Wolfson has held a variety of positions in finance, business and law.
He was most recently the Vice President of Finance and Business Development for 7thOnline, a venture-backed supply chain software company where he was responsible for overseeing legal issues, finance and the development and implementation of corporate strategy, which resulted in annualized revenue growth of over 100% during his tenure. Mr. Wolfson was also a primary interface between the company's management and its board and investors.